Farmakoterapiya vospaleniya i boli: kak sdelat' optimal'nyy vybor?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main purpose of administration of non-steroidal anti-inflammatory drugs (NSAIDs) in acute diseases, chronic diseases and pathological conditions involves relief of pain associated with inflammation, acute trauma and surgery. Clinical experience suggests significant variations in the «response» from individual patients using different NSAIDs. This review presents the results of studies evaluating the clinical efficacy of meloxicam. It is noted that meloxicam shows high efficiency in complex therapy and has a lower risk of adverse reactions among the drugs of this group.

Full Text

Restricted Access

References

  1. Котова О.В. Назначение нестероидных противовоспалительных препаратов: соотношение эффективность/безопасность // Consilium medicum. - 2012. - № 1. - С. 79-82.
  2. Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы // Клиническая фармакология и терапия. -2000. - № 1. - С. 57-64.
  3. Ярославцева Н.В. Мелоксикам в неврологии // Фарматека. - 2006. - № 7.
  4. Argoff C. E. Recent developments in the treatment of osteoarthritis with NSAIDs // Curr. Med. Res. Opin. - 2011. - Vol. 27(7). - P. 1315-27.
  5. Bombarbier C., Laninel L., Reicin A., at al. Comparison of upper gastrointestinal toxity of rofecoxib and naproxen in patient with rheumatoid arthritis. VIGOR Study Group // N. Engl. J. Med. - 2000. - Vol. 343. - P. 1520-28.
  6. Castellsague J., Riera-Guardia N., Calingaert B., et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Safety of Non-SteroidalAnti-Inflammatory Drugs (SOS) Project.
  7. Castellsague J., Pisa F., Rosolen V., et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy// Pharmacoepidemiol. Drug Saf. - 2013. - Vol. 22(4). - P. 365-75.
  8. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2 // Science. - 2002. -Vol. 296. - P. 539-41.
  9. Varas-Lorenzo C., Riera-Guardia N., Calingaert B., et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies // Pharmacoepidemiol. Drug Saf. - 2013. - Vol. 22. - P. 559-70.
  10. FitzGerald G.A., Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2 // New Engl. J. Med. - 2001. - Vol. 345. - P. 433-42.
  11. Hawkey C., et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment // Br. J. Rheumatol. -1998. - Vol. 37. - P. 1142-47.
  12. Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C., et al. Individual NSAIDs and Upper Gastrointestinal Complications. A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project) // Drug Saf. - 2012. - Vol. 35(12). - P. 1127-46.
  13. Kerr S.J., Rowett D.S., Sayer G.P., Whicker S.D., Saltman D.C., Mant A. All-cfuse mortality of elderly Australian veterans using COX-2 selective or non-selektive NSAIDs: a longitudinal study// Br. J. Clin. Pharmacol. - 2011. - Vol. 71(6). -P. 936-42.
  14. Lapeyre-Mestre M., Grolleau S., Montastruc J.L. Adverse drug reations associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006 // Fundam. Clin. Pharmacol. - 2013. - Vol. 27(2). - P. 223-30.
  15. Lenzer J. Pfizer criticized over delay in admitting drug's problems // BMJ. - 2004. -Vol. 239. - P. 935.
  16. del Tacca M., Pasqualetti G., Gori G, Pepe P., et al. Comparative pharmacokinetic and pharmacodynamic evalution of branded and generic formulations of meloxicam in healthy male volunteers // Therapeutics Clinical Risk Management. - 2013. - Vol. 9. - P. 303-11.
  17. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheuma-toidal arthritis. The CLASS study: a randomized controlled trial// JAMA. - 2000. - Vol. 284. -P. 1247-55.
  18. Singh G. Temporary disability due to neck and low back pain in general practice EULAR 2007. The annual European Congress of Rheumatology. Barselona 13-16 June // Ann. Rheum Dis. - 2007. - Vol. 66(Suppl. 2).
  19. Vane J.R. inhibition of prostaglandin synthesis as a mechanism ofaction of aspirin-like drug // Nature (New Biol). -1971. - Vol. 231. -P. 232-35.
  20. Vega J., Goecke H., et al. Nephrotic syndrome and acute tubular necrosis due to meloxicam use //Ren. Fail. - 2012. - Vol. 34(10). -P. 1344-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies